Journal article

Cancer therapies in HIV cure research

TA Rasmussen, JL Anderson, F Wightman, SR Lewin

Current Opinion in HIV and AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017

Abstract

Purpose of review: This article provides an overview of anticancer therapies in various stages of clinical development as potential interventions to target HIV persistence. Recent findings: Epigenetic drugs developed for cancer have been investigated in vitro, ex vivo and in clinical trials as interventions aimed at reversing HIV latency and depleting the amount of virus that persists on antiretroviral therapy. Treatment with histone deacetylase inhibitors induced HIV expression in patients on antiretroviral therapy but did not reduce the frequency of infected cells. Other interventions that may accelerate the decay of latently infected cells, in the presence or absence of latency-reversing ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institute of Allergy and Infectious Diseases


Funding Acknowledgements

This work was partly supported by funding from the American Foundation for AIDS Research, amfAR (grant 109226-58-RGRL); the National Health and Medical Research Council (NHMRC) of Australia; the National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure collaboratory (U19 AI096109); and the L.E.W. Carty Charitable Fund. S.R.L. is an NHMRC Practitioner Fellow.